Results 221 to 230 of about 44,768 (301)

Immunological analysis of myeloid derived suppressor cell (MDSC) : Osteoclast differentiation and immunosenescence

Immunological analysis of myeloid derived suppressor cell (MDSC) : Osteoclast differentiation and immunosenescence
Article 富山大学・富医薬博甲第321号・石戸 克尚・2020/03/24 公表論文 Oral Oncology.
openaire  

Immune endotypes in tuberculosis: Keys to decoding disease complexity

Journal of Internal Medicine, Volume 299, Issue 6, Page 670-693, June 2026.
Abstract Tuberculosis (TB) remains a major global health challenge, with multi‐drug antibiotic regimens as the current standard of care. While effective at killing Mycobacterium tuberculosis, these treatments do not resolve persistent inflammation, prevent lung damage, or reverse immune dysregulation that contribute to poor outcomes and disease ...
Shamila D. Alipoor, Julia Guthrie, Lina Davies Forsman, Andrew R. Di Nardo, Susanna Brighenti   +4 more
wiley   +1 more source

Safe and Localized Lentiviral Gene Delivery via Injectable Mesoporous Scaffolds for Potent Antitumor Immunity

Advanced Materials, Volume 38, Issue 25, 4 May 2026.
This work introduces an injectable mesoporous silica rod scaffold that confines lentiviral vectors to the injection site, enabling localized dendritic cell recruitment and transduction. The platform sustains antigen expression, promotes robust T‐cell activation, and enhances antitumor immunity.
Thanh Loc Nguyen, Yeon‐ju Kim, Jihye Im, Dong Kwang Min, Hyunsu Shin, Thuy An Trinh, Ngoc Man Phan, Min‐jeong Son, Ji‐yeon Shim, Ye‐lim Lee, Yujeong Ha, Kwang‐il Lim, Jaeyun Kim   +12 more
wiley   +1 more source

A New VISTA on combination therapy for negative checkpoint regulator blockade [PDF]

, 2016

core   +1 more source

Cuproptosis and Disulfidptosis Converge to Empower PD‐L1 Checkpoint Therapy via Cadict‐Induced PD‐L1 Translation

Advanced Science, Volume 13, Issue 25, 4 May 2026.
This study introduces Cadict, an EGFR‐targeted nanodrug that co‐delivers cuproptosis and disulfidptosis inducers to overcome immune resistance. Cadict synergistically enhances tumor cytotoxicity and sensitizes cancers to ICIs by upregulating PD‐L1 via an Eif5b‐dependent translation mechanism, fostering a potent antitumor immune response and ...
Shaoqing Huang, Shiyao Song, Xinhua Zhang, Jialing Gao, Ruihan Pu, Jiatong Dai, Xiaoxue Wu, Lulu Chen, Qinghai Li, Xiaoting Liu, Qi Zhou, Mei Song, Weiling He   +12 more
wiley   +1 more source

Daunorubicin conjugated with alpha-fetoprotein selectively eliminates myeloid-derived suppressor cells (MDSCs) and inhibits experimental tumor growth. [PDF]

Cancer Immunol Immunother, 2018
Belyaev NN, Abdolla N, Perfilyeva YV, Ostapchuk YO, Krasnoshtanov VK, Kali A, Tleulieva R.   +6 more
europepmc   +1 more source

GNL3 Orchestrates AR Transcriptional Programs to Drive Castration‐Resistant Prostate Cancer and Immune Evasion

Advanced Science, Volume 13, Issue 26, 8 May 2026.
GNL3 is a novel AR coregulator with dual coactivator and corepressor functions in prostate cancer (PCa). Our study uncovers a previously unrecognized mechanism by which the AR transcriptional complex integrates oncogenic signaling and immune suppression.
Cuiting Zhang, Tin Long Cheong, Nitin Narwade, Dandan Dong, Mokan Deng, Zhengqiang Miao, Zhaoqiang Ding, Wenchao Li, Kate Man Kei Lei, Gong‐Hong Wei, Terence Chuen Wai Poon, Chu‐Xia Deng, Edwin Cheung   +12 more
wiley   +1 more source

Immune Checkpoint Inhibitors and Immunomodulators for Cancer Immunotherapy: Insights Into Resistance and Therapeutic Strategies

Advanced Science, Volume 13, Issue 25, 4 May 2026.
The schematic diagram illustrates the roles of novel immune checkpoints, immunomodulatory factors, cell death and multimodal technologies in cancer immunotherapy. Abstract Cancer immunotherapy has redefined cancer treatment. However, the molecular and cellular basis of immune evasion and therapeutic resistance remains incompletely understood.
Fangquan Chen, Yang Yu, Xiutao Cai, Junhao Lin, Ruirui Liang, Rui Kang, Daolin Tang, Jiao Liu   +7 more
wiley   +1 more source

A Versatile Polymer‐Based In Situ Nanovaccine to Boost Cancer Immunotherapy

Aggregate, Volume 7, Issue 5, May 2026.
A polymer‐based in situ nanovaccine (PCR‐NPs) orchestrates a powerful antitumor immune cascade via integrated antigen release, capture, and lymph nodes transport, eliciting potent CD8+ T cell responses that drive significant tumor inhibition and prolonged mice survival in murine tumor models.
Qi‐Song Tong, Na Shu, Hua Huang, Wei Xu, Wen‐Chuan Xie, Quan Xia, Jin‐Zhi Du   +6 more
wiley   +1 more source

Suppressive role of myeloid-derived suppressor cells (MDSCs) in the microenvironment of breast cancer and targeted immunotherapies. [PDF]

Oncotarget, 2016
Shou D, Wen L, Song Z, Yin J, Sun Q, Gong W.   +5 more
europepmc   +1 more source